America’s Top-Selling Prescription Drugs – a Who’s Who of Blockbusters

According to a recent article in Forbes.com (2/27/06) that was based on figures obtained from IMS Health, a healthcare information company, the top 20 prescription drugs in the U.S. in 2005, with combined sales of $64.6 billion, were as follow:

  1. LIPITOR – Pfizer – Treats high cholesterol: $8.4 billion
  1. ZOCOR – Merck –Treats high cholesterol: $4.4 billion
  1. NEXIUM – AstraZeneca – Treats heartburn: $4.4 billion
  1. PREVACID – Abbott & Takeda – Treats heartburn: $3.8 billion
  1. ADVAIR DISKUS – GlaxoSmithKline – Treats asthma: $3.6 billion
  1. PLAVIX – Bristol-Meyers Squibb & Sanofi-Aventis – Treats heart disease $3.5 billion
  1. ZOLOFT – Pfizer – Treats depression: $3.1 billion
  1. EPOGEN – Amgen – Treats anemia: $3.0 billion
  1. PROCRIT – Johnson & Johnson – Treats anemia: $3.0 billion
  1. ARANESP – Amgen – Treats anemia: $2.8 billion
  1. ENBREL – Amgen & Wyeth – Treats rheumatoid arthritis: $2.7 billion
  1. NORVASC – Pfizer – Treats high blood pressure: $2.6 billion
  1. SEROQUEL – AstraZeneca – Treats schizophrenia: $2.6 billion
  1. EFFEXOR XR – Wyeth – Treats depression: $2.6 billion
  1. ZYPREXA – Eli Lilly – Treats: schizophrenia: $2.5 billion
  1. SINGULAIR – Merck – Treats asthma and allergies: $2.5 billion
  1. PROTONIX – Wyeth – Treats heartburn: $2.4 billion
  1. RISPERDAL – Johnson & Johnson – Treats schizophrenia: $2.3 billion
  1. NEULASTA – Amgen – Treats chemotherapy side effects: $2.2 billion
  1. REMICADE – Johnson & Johnson – Treats rheumatoid arthritis: $2.2 billion
This entry was posted in Health Concerns. Bookmark the permalink.


© 2005-2016 Parker Waichman LLP ®. All Rights Reserved.